Jayant S Goda1, Shirly C Lewis1, Siddartha Laskar1, Sadhna Kannan2, Nehal Khanna1, Hasmukh Jain3, Bhausaheb Bagal3, Sridhar Epari. 1. Department of Radiation Oncology, Tata Memorial Centre, Homi Bhaba National Institute, Mumbai, India. 2. Department of Epidemiology and Clinical Trials Unit, ACTREC, Tata Memorial Centre, Homi Bhaba National Institute, Navi Mumbai, India. 3. Department of Hemato Oncology, Tata Memorial Hospital, Homi Bhaba National Institute, Mumbai, India.
Abstract
BACKGROUND:Radiation therapy for diffuse large B-cell lymphoma (DLBCL) has shown improvement in progression free survival. There is uncertainty about the optimal radiation dose, with heterogeneous doses being used, ranging from 30 to 55 Gy. This trial tests the efficacy of using reduced radiation dose in DLBCL without compromising on long-term outcomes. AIMS: The primary aim is to assess the noninferiority, as assessed by 2-year event free survival (EFS), of a dose de-escalated dose (36 Gy) for DLBCL as compared with a standard dose (45 Gy). METHODS: The Dose Optimization in B cell Lymphomas (DOBL) study is a randomized phase-III noninferiority trial in a uniform cohort of DLBCL patients receiving immunochemotherapy (R-CHOP). Patients with stages I to IV of DLBCL eligible for radiotherapy (RT) after completion of at least four cycles of R-CHOP will be included in the study. Patients will be randomized to standard RT dose of 45 Gy in 25 fractions or reduced dose of 36 Gy in 20 fractions using involved site radiotherapy (ISRT) technique. It is a noninferiority design using a 7% noninferiority margin with a hazard ratio of 1.3, α of 0.05, and β of 0.80. A total of 760 patients will be accrued. Two-year EFS is the primary outcome measure that will be studied. The experimental arm will be stopped and switched over to control arm if on interim analysis, 25% events occur in the experimental arm. DISCUSSION: The study is designed to test the noninferiority of radiation dose de-escalation in a uniform cohort of patients diagnosed with DLBCL and treated with R-CHOP regimen in the post-positron emission tomography (PET) era. The trial is rigorously designed and is straightforward to implement. It is statistically powered to answer if reducing the radiation doses does not compromise the clinical outcome in the given patient cohort. This trial will effectively set the standards in radiotherapy doses for DLBCL in the contemporary era.
RCT Entities:
BACKGROUND: Radiation therapy for diffuse large B-cell lymphoma (DLBCL) has shown improvement in progression free survival. There is uncertainty about the optimal radiation dose, with heterogeneous doses being used, ranging from 30 to 55 Gy. This trial tests the efficacy of using reduced radiation dose in DLBCL without compromising on long-term outcomes. AIMS: The primary aim is to assess the noninferiority, as assessed by 2-year event free survival (EFS), of a dose de-escalated dose (36 Gy) for DLBCL as compared with a standard dose (45 Gy). METHODS: The Dose Optimization in B cell Lymphomas (DOBL) study is a randomized phase-III noninferiority trial in a uniform cohort of DLBCL patients receiving immunochemotherapy (R-CHOP). Patients with stages I to IV of DLBCL eligible for radiotherapy (RT) after completion of at least four cycles of R-CHOP will be included in the study. Patients will be randomized to standard RT dose of 45 Gy in 25 fractions or reduced dose of 36 Gy in 20 fractions using involved site radiotherapy (ISRT) technique. It is a noninferiority design using a 7% noninferiority margin with a hazard ratio of 1.3, α of 0.05, and β of 0.80. A total of 760 patients will be accrued. Two-year EFS is the primary outcome measure that will be studied. The experimental arm will be stopped and switched over to control arm if on interim analysis, 25% events occur in the experimental arm. DISCUSSION: The study is designed to test the noninferiority of radiation dose de-escalation in a uniform cohort of patients diagnosed with DLBCL and treated with R-CHOP regimen in the post-positron emission tomography (PET) era. The trial is rigorously designed and is straightforward to implement. It is statistically powered to answer if reducing the radiation doses does not compromise the clinical outcome in the given patient cohort. This trial will effectively set the standards in radiotherapy doses for DLBCL in the contemporary era.
Authors: A D Krol; H W Berenschot; D Doekharan; S Henzen-Logmans; B van der Holt; M B van 't Veer Journal: Radiother Oncol Date: 2001-03 Impact factor: 6.280
Authors: Lisa Lowry; Paul Smith; Wendi Qian; Stephen Falk; Kim Benstead; Tim Illidge; David Linch; Martin Robinson; Andrew Jack; Peter Hoskin Journal: Radiother Oncol Date: 2011-06-12 Impact factor: 6.280
Authors: Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Laurie H Sehn; Brian Berry; Mukesh Chhanabhai; Catherine Fitzgerald; Karamjit Gill; Paul Hoskins; Richard Klasa; Kerry J Savage; Tamara Shenkier; Judy Sutherland; Randy D Gascoyne; Joseph M Connors Journal: Blood Date: 2006-11-14 Impact factor: 22.113
Authors: Tamara N Shenkier; Nicholas Voss; Randall Fairey; Randy D Gascoyne; Paul Hoskins; Richard Klasa; Paul Klimo; Susan E O'Reilly; Simon Sutcliffe; Joseph M Connors Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544
Authors: Jack Phan; Ali Mazloom; L Jeffrey Medeiros; Tony G Zreik; Christine Wogan; Ferial Shihadeh; Maria Alma Rodriguez; Luis Fayad; Nathan Fowler; Valerie Reed; Patrecia Horace; Bouthaina Shbib Dabaja Journal: J Clin Oncol Date: 2010-08-16 Impact factor: 44.544
Authors: S B Sutcliffe; M K Gospodarowicz; R S Bush; T C Brown; T Chua; H A Bean; R M Clark; A Dembo; P J Fitzpatrick; M V Peters Journal: Radiother Oncol Date: 1985-11 Impact factor: 6.280
Authors: T P Miller; S Dahlberg; J R Cassady; D J Adelstein; C M Spier; T M Grogan; M LeBlanc; S Carlin; E Chase; R I Fisher Journal: N Engl J Med Date: 1998-07-02 Impact factor: 91.245